Hyperparathyroidism, Secondary
"Hyperparathyroidism, Secondary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY.
| Descriptor ID |
D006962
|
| MeSH Number(s) |
C19.642.355.480
|
| Concept/Terms |
Hyperparathyroidism, Secondary- Hyperparathyroidism, Secondary
- Secondary Hyperparathyroidism
- Hyperparathyroidisms, Secondary
- Secondary Hyperparathyroidisms
|
Below are MeSH descriptors whose meaning is more general than "Hyperparathyroidism, Secondary".
Below are MeSH descriptors whose meaning is more specific than "Hyperparathyroidism, Secondary".
This graph shows the total number of publications written about "Hyperparathyroidism, Secondary" by people in this website by year, and whether "Hyperparathyroidism, Secondary" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 3 | 0 | 3 |
| 2008 | 5 | 1 | 6 |
| 2009 | 3 | 0 | 3 |
| 2010 | 0 | 1 | 1 |
| 2011 | 2 | 0 | 2 |
| 2012 | 0 | 1 | 1 |
| 2014 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperparathyroidism, Secondary" by people in Profiles.
-
The cost-effectiveness of extended-release calcifediol versus paricalcitol for the treatment of secondary hyperparathyroidism in stage 3-4 CKD. J Med Econ. 2020 Mar; 23(3):308-315.
-
Parathyroidectomy in the Management of Secondary Hyperparathyroidism. Clin J Am Soc Nephrol. 2018 06 07; 13(6):952-961.
-
Successful Conversion From Parenteral Paricalcitol to Pulse Oral Calcitriol for the Management of Secondary Hyperparathyroidism in Hemodialysis Patients. J Ren Nutr. 2016 07; 26(4):265-9.
-
Clinical uses of 1-alpha-hydroxy-ergocalciferol. Curr Vasc Pharmacol. 2014 Mar; 12(2):306-12.
-
Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis. Pharmacoepidemiol Drug Saf. 2012 Nov; 21(11):1232-9.
-
Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial. Am J Kidney Dis. 2012 Jan; 59(1):58-66.
-
Diuretics and secondary hyperparathyroidism in chronic kidney disease. Nephrol Dial Transplant. 2011 Apr; 26(4):1122-5.
-
Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl. 2010 Aug; (117):S10-21.
-
Association of secondary hyperparathyroidism with CKD progression, health care costs and survival in diabetic predialysis CKD patients. Nephron Clin Pract. 2009; 113(1):c54-61.
-
Cinacalcet lowers serum alkaline phosphatase in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009 Mar; 4(3):673-9.